Article Cited by others


The new factor Xa inhibitor: Apixaban

Bhanwra Sangeeta, Ahluwalia Kaza

Year : 2014| Volume: 5| Issue : 1 | Page no: 12-14

   This article has been cited by
1 Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome
Donal J. Sexton,Declan G. de Freitas,Mark A. Little,Tomas McHugh,Colm Magee,Peter J. Conlon,Conall M. O’Seaghdha
Kidney International Reports. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence
Vincenzo Russo,Anna Rago,Riccardo Proietti,Federica Di Meo,Andrea Antonio Papa,Paolo Calabrò,Antonio D’Onofrio,Gerardo Nigro,Ahmed AlTurki
Therapeutic Advances in Drug Safety. 2017; 8(2): 67
[Pubmed]  [Google Scholar] [DOI]
3 Novel oral anticoagulants in the management of coronary artery disease
Sean R. McMahon,Kathleen Brummel-Ziedins,David J. Schneider
Coronary Artery Disease. 2016; 27(5): 412
[Pubmed]  [Google Scholar] [DOI]
4 Spinal subarachnoid hemorrhage in cortical superficial siderosis after apixaban and clopidogrel therapy
Josef G. Heckmann
Journal of Thrombosis and Thrombolysis. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Natural Products for Antithrombosis
Cen Chen,Feng-Qing Yang,Qian Zhang,Feng-Qin Wang,Yuan-Jia Hu,Zhi-Ning Xia
Evidence-Based Complementary and Alternative Medicine. 2015; 2015: 1
[Pubmed]  [Google Scholar] [DOI]
6 Emergency Reversal of Anticoagulation: Novel Agents
Michael Levine,Joshua N. Goldstein
Current Neurology and Neuroscience Reports. 2014; 14(8)
[Pubmed]  [Google Scholar] [DOI]


Read this article